Therapeutic Secukinumab antibody from the original Cosentyx® commercial drug.
Product batch
| Expiry date
| Brand & Origin
| Price
| 1. Select quantity range | 2. Your quantity | |
|---|---|---|---|---|---|---|
2022.11 |
Cosentyx® LT |
62,00 €
/mg
|
Select quantity:
|
mg |
||
2017.12 |
Cosentyx® DE |
57,50 €
/mg
|
Select quantity:
|
mg |
||
2019.02 |
Cosentyx® DE |
57,50 €
/mg
|
Select quantity:
|
mg |
||
2022.12 |
Cosentyx® DE |
57,50 €
/mg
|
Select quantity:
|
mg |
||
2018.03 |
Cosentyx® DE |
57,50 €
/mg
|
Select quantity:
|
mg |
||
2019.09 |
Cosentyx® DE |
57,50 €
/mg
|
Select quantity:
|
mg |
||
2018.06 |
Cosentyx® DE |
57,50 €
/mg
|
Select quantity:
|
mg |
||
2018.12 |
Cosentyx® DE |
57,50 €
/mg
|
Select quantity:
|
mg |
Evidentic’s analytical service includes a comprehensive array of methods to support the drug development process, including, for example, structure, aggregation, degree of isomerization and N-glycans identification of the active pharmaceutical ingredient (API).
Here you will find the product information for the reference product.
| Drug name | Cosentyx® |
| INN | Secukinumab |
| API type | Secukinumab is a recombinant fully human monoclonal antibody selective for interleukin-17A. Secukinumab is of the IgG1/κ-class produced in Chinese Hamster Ovary (CHO) cells |
| Pharmacotherapeutic group | Immunosuppressants, interleukin inhibitors |
| ATC code | L04AC10 |
| Target of antibody | IL 17A; Synonyms: CTLA8, IL-17, IL-17A, IL17, Ctla-8, Ctla8, Il17, ChIL-17, IL-17F, IL17A, CTLA-8 |
| General function | |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Secukinumab is a fully human IgG1/κ monoclonal antibody that selectively binds to and neutralises the proinflammatory cytokine interleukin-17A (IL-17A). Secukinumab works by targeting IL-17A and inhibiting its interaction with the IL-17 receptor, which is expressed on various cell types including keratinocytes. As a result, secukinumab inhibits the release of proinflammatory cytokines, chemokines and mediators of tissue damage and reduces IL-17A-mediated contributions to autoimmune and inflammatory diseases. Clinically relevant levels of secukinumab reach the skin and reduce local inflammatory markers. As a direct consequence treatment with secukinumab reduces erythema, induration and desquamation present in plaque psoriasis lesions. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. IL-17A plays a key role in the pathogenesis of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis and is up-regulated in lesional skin in contrast to non-lesional skin of plaque psoriasis patients and in synovial tissue of psoriatic arthritis patients. The frequency of IL-17-producing cells was also significantly higher in the subchondral bone marrow of facet joints from patients with ankylosing spondylitis. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | Serum levels of total IL-17A (free and secukinumab-bound IL-17A) are initially increased in patients receiving secukinumab. This is followed by a slow decrease due to reduced clearance of secukinumab-bound IL-17A, indicating that secukinumab selectively captures free IL-17A, which plays a key role in the pathogenesis of plaque psoriasis. In a study with secukinumab, infiltrating epidermal neutrophils and various neutrophil-associated markers that are increased in lesional skin of plaque psoriasis patients were significantly reduced after one to two weeks of treatment. Secukinumab has been shown to lower (within 1 to 2 weeks of treatment) levels of C-reactive protein, which is a marker of inflammation. |
| Original license holder | |
| Marketing authorisation numbers | EU/1/14/980/001 - 007 |
| Marketing authorisation holder | Novartis Europharm Limited Frimley Business Park Camberley GU16 7SR United Kingdom |
| Name of the manufacturer of the biological active substance | |
| Name and address of the manufacturer(s) responsible for batch release | Roche Pharma AG Emil-Barrell-Str. 1, D-79639 Grenzach-Wyhlen Germany |
| Max shelf life | 36 months |
| Storage conditions | 2°C – 8°C |
| List of excipients | Sucrose L-histidine L-histidine hydrochloride-monohydrate Polysorbate 80 |
Do you have any questions about the product, the ordering process or any other detail? Please contact us, we will reply within 24 hours.
At Evidentic, we deal with clinical-grade therapeutic molecules. Think of them as the building blocks for tomorrow’s groundbreaking treatments. These molecules are the active ingredients you’ll find in original drugs prescribed to patients, produced under the strictest quality and safety standards. They’ve also been therapeutically proven through rigorous clinical trials, meaning their effectiveness and safety for treating human diseases have been established. By offering researchers access to these essential tools, we’re fueling the fight for a healthier future.
Unlike some commercially available molecules, Evidentic’s clinical-grade therapeutics aren’t just research possibilities – they’re proven powerhouses! Derived from actual drugs used to treat human diseases, these molecules have already undergone rigorous testing and met the strictest safety and quality standards. This means researchers can focus their energy on groundbreaking discoveries, not questioning the reliability of their tools. With Evidentic, you get the confidence of knowing you’re working with the building blocks for real-world medical advancements.
If you struggle to source clinical-grade biologics you need for your research, Evidentic bridges the gap. We offer royalty-free research consumables (RUO-only) derived from original licensed drugs, giving you access to these critical research tools without the hassle.
But that’s not all. We understand the importance of batch variety in your research. That’s why we’ve built a comprehensive stock library, offering numerous batches of the same active pharmaceutical ingredient (API). This dedication to choice means you can find the exact batch that aligns with your specific research needs.
And because we’re constantly expanding our library, you can be sure we’re actively searching for new batches to add to your research arsenal. With Evidentic, unlock the power of readily available, high-quality research tools and accelerate your scientific breakthroughs.
Evidentic offers access to pharmaceuticals approved by the U.S. FDA (Food and Drug Administration) and/or the EMA (European Medicines Agency). This gives you access to a wider variety of molecules for your research, potentially shortening timelines and boosting the accuracy of your results. Compare EU and US molecules head-to-head, and accelerate your early drug development projects with access to these high-quality research tools. Contact us today to explore the possibilities!
Evidentic’s aliquots from approved pharnaceuticals can be used for analytical, in vitro research, typically executed in early drug development stage of drug discovery programs, like:
